PLT012

PLT012 promisingly exhibited anti-tumor responses in both Yumm1.7 melanoma and MC38 colorectal cancer models^[1].
PLT012 (10 mg/kg, i.p. once) has the potential to restore anti-tumor immunity against HCC by targeting CD36-mediated immune regulations in CTNNB1^N90/MYC^OEHCC-bearing mice^[1].
PLT012 (10 mg/kg, i.p., once every three days, 18 days) is capable of restoring anti-tumor responses in HCC and might also improve responsiveness to PD-1 blockade in the MYC^OE/p53^KO HCC mice model^[1].
PLT012 (10 mg/kg, i.p., once every three days for 5 doses) remodels the immunosuppressive TME in β-catenin-mutant HCC, effectively activating anti-tumor T-cell immunity in CTNNB1^N90/MYC^OEHCC-bearing mice^[1].
PLT012 () significantly enhances anti-tumor efficacy when combination with an anti-PD-L1 monoclonal antibody or anti-VEGF and anti-PD-L1, and achieved a >70% overall positive response rate and a 45% complete response rate when combinates with anti-PD-L1 and anti-VEGF in CTNNB1^N90/MYC^OEHCC-bearing mice^[1].
PLT012 () restrains HCC progression under conditions of high dietary lipid intake in CTNNB1N90/MYCOE HCC-bearing mice, whether fed a standard chow diet (CD) or a high-fat Western (WD) diet^[1].
PLT012 () reprograms the tumor immune microenvironment, thereby restricting colon cancer liver metastasis and enhancing sensitivity to PD-1 blockade in mice MC38 xenografts models^[1].
PLT012 (0-200 mg/kg, once a week, for 5 weeks) is well-tolerated in non-human primates (cynomolgus monkeys)^[1].